Clinical trial
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic…
NCT00433446 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00433446 |
|---|---|
| Title | S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy |
| Official title | A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | CNTO 328 |
| Enrollment | 62 |
| Start date | Apr 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | Jul 1, 2011 |
| First posted | Feb 12, 2007 |
| Last update posted | Feb 5, 2013 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: